Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1992 Mar;60(3):1061–1068. doi: 10.1128/iai.60.3.1061-1068.1992

Binding of monoclonal antibody specific for domain Ia/II of Pseudomonas aeruginosa exotoxin A at pH 4 strongly neutralizes exotoxin A-induced cytotoxicity in cell culture and in vivo.

H Ohtsuka 1, K Horigome 1, A Higuchi 1, N Nomura 1, H Ochi 1, S Yokota 1, T Kohzuki 1, H Noguchi 1
PMCID: PMC257594  PMID: 1371763

Abstract

Mouse monoclonal antibodies (MAbs) against Pseudomonas aeruginosa exotoxin A (Ex-A) were established, and 4 of 20 MAbs were extensively studied for analysis of the structure-function relationship of Ex-A. IN vivo experiments demonstrated that MAb Ex-3C7 protected mice either injected with Ex-A or infected with Ex-A-producing P. aeruginosa from death caused by Ex-A at the highest rate, followed by MAbs Ex-4F2 and Ex-8H5, in that order. MAb Ex-2A10 failed to rescue the mice. MAb Ex-3C7 (immunoglobulin G1 [IgG1]) inhibited incorporation of Ex-A into target cells and strongly neutralized cytotoxicity in cell culture but did not inhibit an enzymatic activity of Ex-A, ADP-ribosyltransferase, at all. The MAb also bound Ex-A, even at a low pH of 4, and recognized amino acid residues 241 to 297 (domain Ia/II), suggesting that MAb Ex-3C7 can interfere with the conformational change and/or processing of Ex-A by keeping a complex of Ex-A and antibody stable at low pH in the phagolysosome. MAb Ex-4F2 (IgG1), which recognizes residues 550 to 590 (domain III), strongly inhibited Ex-A incorporation and neutralized cytotoxicity in cell culture but only weakly inhibited ADP-ribosyltransferase. MAb Ex-8H5 (IgG1), which recognizes residues 591 to 613 (domain III), also inhibited cytotoxicity in cell culture, but weakly. In contrast to the above three MAbs, MAb Ex-2A10 (IgG2b) greatly inhibited ADP-ribosyltransferase but showed no inhibition of Ex-A incorporation and no neutralizing activity against cell toxicity. A line of evidence indicates that (i) domain Ia/II plays an important role in the pathogenesis of Ex-A and (ii) MAbs that inhibit an intracellular postbinding process, such as conformational change, processing, and translocation of Ex-A in target cells, can display potent inhibitory activity against cytotoxicity in vivo, as well as in cell culture, and would be a good candidate for therapy of pseudomonal infections.

Full text

PDF
1061

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allured V. S., Collier R. J., Carroll S. F., McKay D. B. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. Proc Natl Acad Sci U S A. 1986 Mar;83(5):1320–1324. doi: 10.1073/pnas.83.5.1320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Carroll S. F., Collier R. J. Active site of Pseudomonas aeruginosa exotoxin A. Glutamic acid 553 is photolabeled by NAD and shows functional homology with glutamic acid 148 of diphtheria toxin. J Biol Chem. 1987 Jun 25;262(18):8707–8711. [PubMed] [Google Scholar]
  3. Chaudhary V. K., Jinno Y., FitzGerald D., Pastan I. Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity. Proc Natl Acad Sci U S A. 1990 Jan;87(1):308–312. doi: 10.1073/pnas.87.1.308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chia J. K., Pollack M., Avigan D., Steinbach S. Functionally distinct monoclonal antibodies reactive with enzymatically active and binding domains of Pseudomonas aeruginosa toxin A. Infect Immun. 1986 Jun;52(3):756–762. doi: 10.1128/iai.52.3.756-762.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chow J. T., Chen M. S., Wu H. C., Hwang J. Identification of the carboxyl-terminal amino acids important for the ADP-ribosylation activity of Pseudomonas exotoxin A. J Biol Chem. 1989 Nov 5;264(31):18818–18823. [PubMed] [Google Scholar]
  6. Douglas C. M., Collier R. J. Exotoxin A of Pseudomonas aeruginosa: substitution of glutamic acid 553 with aspartic acid drastically reduces toxicity and enzymatic activity. J Bacteriol. 1987 Nov;169(11):4967–4971. doi: 10.1128/jb.169.11.4967-4971.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Galloway D. R., Hedstrom R. C., Pavlovskis O. R. Production and characterization of monoclonal antibodies to exotoxin A from Pseudomonas aeruginosa. Infect Immun. 1984 May;44(2):262–267. doi: 10.1128/iai.44.2.262-267.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gray G. L., Smith D. H., Baldridge J. S., Harkins R. N., Vasil M. L., Chen E. Y., Heyneker H. L. Cloning, nucleotide sequence, and expression in Escherichia coli of the exotoxin A structural gene of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A. 1984 May;81(9):2645–2649. doi: 10.1073/pnas.81.9.2645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hayashi R. Carboxypeptidase Y. Methods Enzymol. 1976;45:568–587. doi: 10.1016/s0076-6879(76)45051-6. [DOI] [PubMed] [Google Scholar]
  10. Hwang J., Chen M. S. Structure and function relationship of Pseudomonas exotoxin A. An immunochemical study. J Biol Chem. 1989 Feb 5;264(4):2379–2384. [PubMed] [Google Scholar]
  11. Hwang J., Fitzgerald D. J., Adhya S., Pastan I. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell. 1987 Jan 16;48(1):129–136. doi: 10.1016/0092-8674(87)90363-1. [DOI] [PubMed] [Google Scholar]
  12. Idziorek T., FitzGerald D., Pastan I. Low pH-induced changes in Pseudomonas exotoxin and its domains: increased binding of Triton X-114. Infect Immun. 1990 May;58(5):1415–1420. doi: 10.1128/iai.58.5.1415-1420.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Jinno Y., Chaudhary V. K., Kondo T., Adhya S., FitzGerald D. J., Pastan I. Mutational analysis of domain I of Pseudomonas exotoxin. Mutations in domain I of Pseudomonas exotoxin which reduce cell binding and animal toxicity. J Biol Chem. 1988 Sep 15;263(26):13203–13207. [PubMed] [Google Scholar]
  14. Jinno Y., Ogata M., Chaudhary V. K., Willingham M. C., Adhya S., FitzGerald D., Pastan I. Domain II mutants of Pseudomonas exotoxin deficient in translocation. J Biol Chem. 1989 Sep 25;264(27):15953–15959. [PubMed] [Google Scholar]
  15. Lory S., Collier R. J. Expression of enzymic activity by exotoxin A from Pseudomonas aeruginosa. Infect Immun. 1980 May;28(2):494–501. doi: 10.1128/iai.28.2.494-501.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Madshus I. H., Collier R. J. Effects of eliminating a disulfide bridge within domain II of Pseudomonas aeruginosa exotoxin A. Infect Immun. 1989 Jul;57(7):1873–1878. doi: 10.1128/iai.57.7.1873-1878.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Manhart M. D., Morris R. E., Bonventre P. F., Leppla S., Saelinger C. B. Evidence for pseudomonas exotoxin A receptors on plasma membrane of toxin-sensitive lm fibroblasts. Infect Immun. 1984 Sep;45(3):596–603. doi: 10.1128/iai.45.3.596-603.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ogata M., Pastan I., FitzGerald D. Analysis of Pseudomonas exotoxin activation and conformational changes by using monoclonal antibodies as probes. Infect Immun. 1991 Jan;59(1):407–414. doi: 10.1128/iai.59.1.407-414.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ohtsuka H., Higuchi A., Nomura N., Horigome K., Kohzuki T., Nakamori Y., Noguchi H. The carboxyl terminal amino acid residues of Pseudomonas aeruginosa exotoxin A involved in cell toxicity and pathogenesis, characterized by a neutralizing human monoclonal antibody. Biochem Biophys Res Commun. 1991 Nov 14;180(3):1498–1504. doi: 10.1016/s0006-291x(05)81365-8. [DOI] [PubMed] [Google Scholar]
  20. Ohtsuka H., Horigome K., Ochi H., Nishimoto T., Kozuki T., Kato M., Okuda T., Noguchi H. Production and characterization of human monoclonal antibody recognizing the N-terminal residues of Pseudomonas aeruginosa exotoxin A. Hybridoma. 1991 Apr;10(2):297–307. doi: 10.1089/hyb.1991.10.297. [DOI] [PubMed] [Google Scholar]
  21. Pollack M. The role of exotoxin A in pseudomonas disease and immunity. Rev Infect Dis. 1983 Nov-Dec;5 (Suppl 5):S979–S984. doi: 10.1093/clinids/5.supplement_5.s979. [DOI] [PubMed] [Google Scholar]
  22. Siegall C. B., Chaudhary V. K., FitzGerald D. J., Pastan I. Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin. J Biol Chem. 1989 Aug 25;264(24):14256–14261. [PubMed] [Google Scholar]
  23. Takamatsu K., Uchida T., Okada Y. Specific purification of elongation factor 2 and isolation of its antibody. Biochem Biophys Res Commun. 1986 Jan 29;134(2):1015–1021. doi: 10.1016/s0006-291x(86)80522-8. [DOI] [PubMed] [Google Scholar]
  24. Wozniak D. J., Hsu L. Y., Galloway D. R. His-426 of the Pseudomonas aeruginosa exotoxin A is required for ADP-ribosylation of elongation factor II. Proc Natl Acad Sci U S A. 1988 Dec;85(23):8880–8884. doi: 10.1073/pnas.85.23.8880. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES